NASDAQ$RMTI
Rockwell Medical Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results and business update for Q2 2020.
Rockwell Medical reported a 7.1% increase in net sales for the second quarter of 2020, primarily due to increased demand for dialysis concentrates products, and made progress in the commercialization of Triferic Dialysate despite COVID-19 challenges.
- Q2 2020 revenue was $15.9 million.
- Contracted clinics increased by 44% quarter-over-quarter.
- Contracted annualized treatment volume for Triferic Dialysate reached over 400,000.
- Cash, cash equivalents, and investments available-for-sale totaled $40.0 million as of June 30, 2020.
Headline financials
Revenue & EPS history
Rockwell Medical · Revenue · Quarterly
$15.9M
Forward guidance
Rockwell Medical expects to initiate a sample evaluation program for Triferic AVNU during the third quarter of 2020 in order to prepare for a commercial launch and will monitor the evaluation program in relation to the COVID-19 pandemic through the balance of the year.
Tailwinds
- Initiate a sample evaluation program for Triferic AVNU during the third quarter of 2020
- Prepare for a commercial launch of Triferic AVNU
- Expect regulatory approval in Canada in mid-2021
- Commercial introduction to Triferic AVNU
- Expect Triferic AVNU to be available commercially during the fourth quarter of 2020
Headwinds
- Impact of COVID-19 on business and operating results
- Challenges inherent in new product development
- Success of commercialization strategy
- Anticipated research and development expenses
- Monitor the evaluation program in relation to the COVID-19 pandemic through the balance of the year
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
-3.1%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-3.0%
Avg return
30 days after
38%
24 / 63 earnings
Positive
+28.2%
Q3 2022
Best reaction
-43.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -13.0% | -11.3% | — | |
| Q1 2026 | -3.6% | +2.8% | -18.2% | |
| Q3 2025 | -9.2% | -17.1% | -12.4% | |
| Q1 2025 | -6.4% | -9.8% | -11.6% | |
| Q4 2024 | -20.5% | -31.8% | -41.5% | |
| Q3 2024 | -43.4% | -49.2% | -55.5% | |
| Q2 2024 | +22.6% | +35.6% | +68.4% | |
| Q1 2024 | +0.6% | +4.1% | +8.2% | |
| Q4 2023 | +3.6% | +0.0% | -12.1% | |
| Q3 2023 | +12.2% | +5.1% | -11.2% | |
| Q2 2023 | -7.4% | -25.8% | -28.5% | |
| Q1 2023 | -4.5% | -3.7% | +71.8% | |
| Q4 2022 | +14.6% | +18.4% | +74.7% | |
| Q3 2022 | +28.2% | +19.4% | +0.0% | |
| Q2 2022 | +12.0% | +7.1% | -14.1% | |
| Q1 2022 | +3.0% | -17.3% | -34.7% | |
| Q4 2021 | -13.6% | -11.4% | -27.3% | |
| Q3 2021 | -7.7% | -7.7% | -21.2% | |
| Q2 2021 | -6.2% | -10.8% | -4.6% | |
| Q1 2021 | -2.2% | -4.3% | +0.0% | |
| Q4 2020 | +4.5% | -1.8% | -13.5% | |
| Q3 2020 | +1.1% | +5.6% | +33.7% | |
| Q2 2020 | +4.2% | +0.0% | -26.3% | |
| Q1 2020 | -4.7% | -12.9% | -9.0% | |
| Q4 2019 | -42.7% | -25.0% | -22.6% | |
| Q3 2019 | +5.4% | +12.4% | +23.7% | |
| Q2 2019 | -5.6% | +2.0% | +9.3% | |
| Q1 2019 | -7.5% | -11.9% | -25.6% | |
| Q4 2018 | +3.0% | +23.9% | +4.7% | |
| Q3 2018 | +8.9% | +12.3% | -16.2% | |
| Q2 2018 | -15.5% | -12.4% | -13.6% | |
| Q1 2018 | -2.5% | +5.8% | -8.8% | |
| Q4 2017 | -17.5% | -18.3% | -14.1% | |
| Q3 2017 | +9.6% | +11.6% | +3.4% | |
| Q2 2017 | -4.2% | -1.5% | -5.4% | |
| Q1 2017 | -1.2% | -9.1% | +9.3% | |
| Q4 2016 | +10.0% | +10.2% | +10.6% | |
| Q3 2016 | -20.5% | -3.5% | +27.3% | |
| Q2 2016 | -8.9% | -8.1% | -10.2% | |
| Q1 2016 | +19.7% | — | — | |
| Q4 2015 | -36.8% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q2 2015 | +11.5% | — | — | |
| Q1 2015 | +12.9% | — | — | |
| Q4 2014 | -6.6% | — | — | |
| Q3 2014 | +5.7% | — | — | |
| Q2 2014 | +0.1% | — | — | |
| Q1 2014 | -8.5% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +0.6% | — | — | |
| Q1 2013 | -7.6% | — | — | |
| Q4 2012 | -19.9% | — | — | |
| Q3 2012 | -3.3% | — | — | |
| Q2 2012 | -6.4% | — | — | |
| Q1 2011 | -0.2% | — | — | |
| Q1 2012 | +1.0% | — | — | |
| Q4 2011 | -4.4% | — | — | |
| Q3 2011 | -9.3% | — | — | |
| Q3 2010 | -9.3% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q2 2010 | -0.1% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro